Larry A Weinrauch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7830915/publications.pdf

Version: 2024-02-01

		279487	329751
105	1,619	23	37
papers	citations	h-index	g-index
106	106	106	1589
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A Population-Based Study of Appetite-Suppressant Drugs and the Risk of Cardiac-Valve Regurgitation. New England Journal of Medicine, 1998, 339, 719-724.	13.9	257
2	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.	2.2	83
3	Myocardial dysfunction without coronary artery disease in diabetic renal failure. American Journal of Cardiology, 1979, 43, 193-199.	0.7	82
4	Effect of glycemic control on heart rate variability in type I diabetic patients with cardiac autonomic neuropathy. American Journal of Cardiology, 1999, 84, 687-691.	0.7	76
5	Short- and Long-Term Reproducibility of Heart Rate Variability in Patients With Long-Standing Type I Diabetes Mellitus. American Journal of Cardiology, 1997, 80, 1198-1202.	0.7	51
6	Provocative testing for coronary arterial spasm: Rationale, risk and clinical illustrations. American Journal of Cardiology, 1977, 40, 624-629.	0.7	49
7	Metoclopramide-Induced Neuroleptic Malignant Syndrome. Archives of Internal Medicine, 1987, 147, 1495.	4.3	48
8	Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. American Journal of Cardiology, 1999, 84, 449-453.	0.7	43
9	Relationship Between Autonomic Function and Progression of Renal Disease in Diabetic Proteinuria Clinical Correlations and Implications for Blood Pressure Control. American Journal of Hypertension, 1998, 11, 302-308.	1.0	42
10	Improved glycemic control induces regression of left ventricular mass in patients with type 1 diabetes mellitus. International Journal of Cardiology, 2004, 94, 47-51.	0.8	38
11	Pathophysiology of Obesity-Related Renal Dysfunction Contributes to Diabetic Nephropathy. Current Diabetes Reports, 2012, 12, 440-446.	1.7	34
12	Marked abnormalities in heart rate variability are associated with progressive deterioration of renal function in type I diabetic patients with overt nephropathy. International Journal of Cardiology, 2002, 86, 281-287.	0.8	33
13	Infection and Malignancy Outweigh Cardiovascular Mortality in Kidney Transplant Recipients: Post Hoc Analysis of the FAVORIT Trial. American Journal of Medicine, 2018, 131, 165-172.	0.6	33
14	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Research and Care, 2014, 2, e000011.	1.2	31
15	Cause of Death in Patients With Diabetic CKD Enrolled in theÂTrial to Reduce Cardiovascular Events With Aranesp TherapyÂ(TREAT). American Journal of Kidney Diseases, 2015, 66, 429-440.	2.1	29
16	Mortality following a cardiovascular or renal event in patients with type 2 diabetes in the ALTITUDE trial. European Heart Journal, 2015, 36, 2463-2469.	1.0	29
17	Decreased Insulin Requirement in Acute Renal Failure in Diabetic Nephropathy. Archives of Internal Medicine, 1978, 138, 399.	4.3	28
18	Preoperative evaluation for diabetic renal transplantation: Impact of clinical, laboratory, and echocardiographic parameters on patient and allograft survival. American Journal of Medicine, 1992, 93, 19-28.	0.6	28

#	Article	IF	Citations
19	Application of the Ambulatory 24-Hour Electrocardiogram in the Prediction of Cardiac Death in Dialysis Patients. Archives of Internal Medicine, 1988, 148, 2381.	4.3	27
20	Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy. Metabolism: Clinical and Experimental, 2000, 49, 1491-1495.	1.5	26
21	Improved glycemic control and platelet function abnormalities in diabetic patients with microvascular disease. Metabolism: Clinical and Experimental, 2000, 49, 88-91.	1.5	25
22	Decreased serum lithium during verapamil therapy. American Heart Journal, 1984, 108, 1378-1380.	1.2	23
23	Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection. International Journal of Molecular Sciences, 2018, 19, 2465.	1.8	23
24	Risk factors for thromboembolic events in renal failure. International Journal of Cardiology, 2005, 101, 19-25.	0.8	21
25	Smoking and outcomes in kidney transplant recipients: a post hoc survival analysis of the FAVORIT trial. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 155-164.	0.8	20
26	Effects of Smoking on Solid Organ Transplantation Outcomes. American Journal of Medicine, 2019, 132, 413-419.	0.6	19
27	Usefulness of left ventricular size and function in predicting survival in chronic dialysis patients with diabetes mellitus. American Journal of Cardiology, 1992, 70, 300-303.	0.7	18
28	Relation of Heart Rate Variability and Serum Lipoproteins in Type 1 Diabetes Mellitus and Chronic Stable Angina Pectoris. American Journal of Cardiology, 1998, 81, 945-949.	0.7	17
29	Cardiorenal Failure: Treatment of Refractory Biventricular Failure by Peritoneal Dialysis. Uremia Investigation, 1984, 8, 1-8.	0.1	16
30	C-Reactive Protein, Fibrinogen, and Cardiovascular Risk. New England Journal of Medicine, 2013, 368, 84-86.	13.9	16
31	Contrast media-induced acute renal failure. Use of creatinine clearance to determine risk in elderly diabetic patients. JAMA - Journal of the American Medical Association, 1978, 239, 2018-2019.	3.8	16
32	Cardiac Conduction Defects Associated with Aortic and Mitral Valve Calcification in Dialysis Patients. Renal Failure, 1990, 12, 103-107.	0.8	14
33	Increased Infection Rate in Diabetic Dialysis Patients Exposed to Cocaine. American Journal of Kidney Diseases, 1991, 18, 349-352.	2.1	14
34	Left Ventricular Mass Reduction in Type 1 Diabetic Patients With Nephropathy. Journal of Clinical Hypertension, 2005, 7, 159-164.	1.0	14
35	Fibrinogen and Factor VII Levels Improve With Glycemic Control in Patients With Type 1 Diabetes Mellitus Who Have Microvascular Complications. Archives of Internal Medicine, 2001, 161, 98.	4.3	13

36 Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50

#	Article	IF	CITATIONS
37	Amyloid Deposition in Serosal Membranes. Archives of Internal Medicine, 1984, 144, 630.	4.3	12
38	Autonomic function in type I diabetes mellitus complicated by nephropathy a cross-sectional analysis in the presymptomatic phase. American Journal of Hypertension, 1995, 8, 782-789.	1.0	12
39	Variations in glucose/C-peptide ratio in patients with type 2 diabetes associated with renal function. Diabetes Research and Clinical Practice, 2019, 150, 1-7.	1.1	12
40	Sodium–glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions. International Journal of Nephrology and Renovascular Disease, 2017, Volume 10, 153-158.	0.8	11
41	Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney. International Journal of Nephrology and Renovascular Disease, 2009, 2, 39.	0.8	10
42	Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review. CKJ: Clinical Kidney Journal, 2016, 9, 705-712.	1.4	10
43	Pulsatile intermittent intravenous insulin therapy for attenuation of retinopathy and nephropathy in type 1 diabetes mellitus. Metabolism: Clinical and Experimental, 2010, 59, 1429-1434.	1.5	9
44	Diabetic microvascular complications: possible targets for improved macrovascular outcomes. International Journal of Nephrology and Renovascular Disease, 2011, 4, 1.	0.8	9
45	Preliminary Screening of the Relationship of Serum Lipids to Survival of Chronic Dialysis Patients. Renal Failure, 1993, 15, 203-209.	0.8	8
46	Regression of Left Ventricular Hypertrophy in Diabetic Nephropathy: Loss of Parasympathetic Function Predicts Response to Treatment. Journal of Clinical Hypertension, 2006, 8, 330-335.	1.0	8
47	A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria. Metabolism: Clinical and Experimental, 2007, 56, 1453-1457.	1.5	8
48	Resistant Hypertension in Diabetes Mellitus. Current Diabetes Reports, 2014, 14, 516.	1.7	8
49	Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients. Journal of Clinical Hypertension, 2016, 18, 878-883.	1.0	8
50	Amyloid deposition in serosal membranes. Its occurrence with cardiac tamponade, bilateral ureteral obstruction, and gastrointestinal bleeding. Archives of Internal Medicine, 1984, 144, 630-632.	4.3	8
51	Metforminâ€6GLT2, Dehydration, and Acidosis Potential. Journal of the American Geriatrics Society, 2017, 65, e101-e102.	1.3	7
52	Acute renal failure after cerebral arteriography in a diabetic patient. Neuroradiology, 1977, 12, 197-199.	1.1	6
53	Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit. Metabolism: Clinical and Experimental, 2009, 58, 488-491.	1.5	6
54	Aiming for the Best Control of Glycemia in Patients With Heart Failure and Type 2 Diabetes. Journal of the American College of Cardiology, 2009, 54, 429-431.	1.2	6

#	Article	IF	CITATIONS
55	The autonomic nervous system and renal physiology. International Journal of Nephrology and Renovascular Disease, 2013, 6, 149.	0.8	6
56	Epigenetics. Journal of the American College of Cardiology, 2018, 72, 1275-1277.	1.2	6
57	The Diabetic Cardiorenal Nexus. International Journal of Molecular Sciences, 2022, 23, 7351.	1.8	6
58	Elimination of Requirement for Exogenous Insulin Therapy in Diabetic Renal Failure. Clinical and Experimental Dialysis and Apheresis, 1982, 6, 75-83.	0.1	5
59	Prospective evaluation of autonomic dysfunction in aggressive management of diabetic microangiopathy. American Journal of Hypertension, 1999, 12, 1135-1139.	1.0	5
60	Risk Stratification of Resistant Hypertension in Chronic KidneyÂDisease. Journal of the American College of Cardiology, 2013, 61, 2468-2470.	1.2	5
61	Does calcium channel blockade have a role in prevention of expression of sepsis in renal transplant recipients?. International Journal of Nephrology and Renovascular Disease, 2016, Volume 9, 291-295.	0.8	5
62	Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. International Journal of Nephrology and Renovascular Disease, 2017, Volume 10, 233-242.	0.8	5
63	Calcium channel blockade and survival in recipients of successful renal transplant: an analysis of the FAVORIT trial results. International Journal of Nephrology and Renovascular Disease, 2017, Volume 11, 1-7.	0.8	5
64	Do biologic markers predict cardiovascular end points in diabetic end-stage renal disease? A prospective longitudinal study. CKJ: Clinical Kidney Journal, 2013, 6, 599-603.	1.4	4
65	Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines. CKJ: Clinical Kidney Journal, 2017, 10, 661-665.	1.4	4
66	Mapping Directions for the Cardiorenal Conundrum. Journal of the American College of Cardiology, 2008, 51, 1275-1276.	1.2	3
67	Disruption of Coronary Vasomotor Function: The Coronary Spasm Syndrome. Cardiovascular Therapeutics, 2012, 30, e66-73.	1.1	3
68	Solid Organ Transplantation. JACC: Heart Failure, 2018, 6, 348-349.	1.9	3
69	SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis. Journal of Diabetes and Its Complications, 2021, 35, 107761.	1.2	3
70	A pilot study to assess utility of changes in elements of the Diabetes Impact Management Scale in evaluating diabetic patients for progressive nephropathy. Metabolism: Clinical and Experimental, 2009, 58, 492-496.	1.5	2
71	What have trials of pulsatile intravenous insulin taught us?. Metabolism: Clinical and Experimental, 2010, 59, 764-765.	1.5	2
72	The impact of a prior history of cardiovascular events on outcomes in patients on renal replacement therapy. International Journal of Cardiology, 2012, 157, 146-148.	0.8	2

#	Article	IF	CITATIONS
73	Response to Panagiotis. Journal of Clinical Hypertension, 2016, 18, 1077-1078.	1.0	2
74	The Fight Against Multidrug-Resistant Bacteria. Annals of Internal Medicine, 2017, 166, 77.	2.0	2
75	Diabetes and the solid organ transplant recipient. Diabetes Research and Clinical Practice, 2018, 146, 220-224.	1.1	2
76	Nephrotoxicity from angiographic contrast material. A prospective study. American Journal of Medicine, 1982, 72, A29.	0.6	1
77	Ultrafiltration in End-Stage Heart Failure. Journal of the American College of Cardiology, 2012, 60, 1913-1915.	1.2	1
78	Letter by Weinrauch and Barkoudah Regarding Article, "Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation. Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registryâ€. Circulation, 2015, 131, e335.	1.6	1
79	Cardiovascular Risk Reduction and theÂCommunity Pharmacist. Journal of the American College of Cardiology, 2016, 67, 2855-2857.	1.2	1
80	Is Skipping Breakfast aÂMarker for CurrentÂSmoking?. Journal of the American College of Cardiology, 2018, 71, 707-708.	1.2	1
81	The Reply. American Journal of Medicine, 2018, 131, e349-e351.	0.6	1
82	Renal transplant outcomes and diabetes. BMJ Open Diabetes Research and Care, 2021, 9, e002294.	1.2	1
83	Patients' perceptions of their MI predicted return to work and functioning. ACP Journal Club, 1996, 125, 76.	0.1	1
84	Insulin Resistance With Pancreatic Pseudocyst Relieved by Percutaneous Drainage. Archives of Internal Medicine, 1983, 143, 1244.	4.3	0
85	Amyloid Deposition in Serosal Membranes-Reply. Archives of Internal Medicine, 1985, 145, 2264.	4.3	0
86	Ventricular arrhythmia and long-term survival with maintenance dialysis. Lancet, The, 1992, 340, 670.	6.3	0
87	Ethics and Organ Use. Archives of Internal Medicine, 1995, 155, 2013.	4.3	0
88	Relationship Between Autonomic Function and Plasma Fibrinogen, Viscosity, and Elements of Fibrinolytic Activity in Diabetic Nephropathy. American Journal of Hypertension, 1997, 10, 454-461.	1.0	0
89	How Can the Care of Diabetic ESRD Patients Be Improved?. Seminars in Dialysis, 1991, 4, 16-18.	0.7	0
90	Stroke Center Designation and Mortality. JAMA - Journal of the American Medical Association, 2011, 305, 1656.	3.8	0

#	Article	IF	CITATIONS
91	Surgery vs Watchful Waiting for Mitral Regurgitation. JAMA - Journal of the American Medical Association, 2013, 310, 2099.	3.8	0
92	Sudden Death in Adolescent Athletes. Journal of the American College of Cardiology, 2014, 63, 1931.	1.2	0
93	Getting Lost Among the Guidelines: The Difference Between Patient-focused Treatment and Population Management. American Journal of Medicine, 2015, 128, e73.	0.6	0
94	Diabetic microvascular triopathy, smoking, and risk of cardiovascular events. Lancet Diabetes and Endocrinology,the, 2016, 4, 888.	5 . 5	0
95	Diabetes in the Older Patient: A Role for C-Peptide?. American Journal of Medicine, 2017, 130, e545.	0.6	0
96	Flosequinan. JACC: Heart Failure, 2018, 6, 84.	1.9	0
97	Wisely Choosing: Aging, Precision, and Medicine. American Journal of Medicine, 2018, 131, e63.	0.6	0
98	End-Stage Renal Disease and ArrhythmicÂDeath. JACC: Clinical Electrophysiology, 2018, 4, 975-976.	1.3	0
99	Economic Outcomes and Geographic Trending in Patients With Limiting Angina Pectoris. American Journal of Cardiology, 2019, 123, 1009.	0.7	0
100	Comparison of Outcomes With Metformin and Sulfonylureas in Chronic Kidney Disease. Mayo Clinic Proceedings, 2020, 95, 1551-1552.	1.4	0
101	Role of diabetes in residual risk among statin treated patients with prior cardiovascular events. Journal of Diabetes and Its Complications, 2021, 35, 107800.	1.2	0
102	Pollution and Organ Transplantation. Journal of the American College of Cardiology, 2020, 75, 2875-2876.	1.2	0
103	The importance of bubbles at high altitude. American Journal of Medicine, 2022, , .	0.6	0
104	Inadequacy of fractional excretion of sodium test. Archives of Internal Medicine, 1981, 141, 818-818.	4.3	0
105	ST-segment depression and mortality after myocardial infarction. ACP Journal Club, 1994, 120, 19.	0.1	0